A man in his late 70s, Albert has always led a full life. From his home in rural Texas, he runs his family farm, oversees ...

Health Minister Dr Aaron Motsoaledi has revealed that medicines frequently affected by stock disruptions include antibiotics, tuberculosis medicines, oncology products, insulin, and selected ...

Health Minister Dr Aaron Motsoaledi reveals the ongoing challenges of medicine stock disruptions in South Africa, detailing ...

AstraZeneca shares tumbled nearly 10% in London after a late-stage trial for an experimental heart disease failed to meet its ...

The FDA expands approval of Skyrizi (risankizumab-rzaa) for pediatric patients aged 6 years and older with moderate to severe plaque psoriasis or active psoriatic arthritis.

Hospital use drugs hitting shortage deadlines in July include six critical medications with FDA dates, impacting supply and patient care management.

Retractable Technologies, Inc. ("Retractable") (NYSE American: RVP) announced today that its Board of Directors has declared dividends to holders of its Series II Class B and Series III Class B ...

It will allow Medicare participants to get GLP-1 drugs for weight loss by paying only a $50-a-month co-pay, The Washington ...

On June 27, AbbVie Inc. (NYSE:ABBV) said the Food and Drug Administration approved Skyrizi for pediatric patients with ...

Week-16 results showed that 69% of risankizumab-treated patients achieved a static Physician Global Assessment of Psoriasis ...

Indications now include pediatric plaque psoriasis and active PsA starting at age 6, positioning risankizumab as the first US-approved IL-23(p19) inhibitor for <40 kg pediatric patients. Weight-tiered ...

FDA cleared a Besremi prefilled pen as a second delivery option to the prefilled syringe, with no changes to indication, dose schedule, or established safety profile. Ropeginterferon alfa-2b is ...